Suppr超能文献

HLA I 类等位基因多态性影响肽结合和 KIR 相互作用与特应性皮炎患儿缓解相关:一项纵向研究。

HLA Class I Polymorphisms Influencing Both Peptide Binding and KIR Interactions Are Associated with Remission among Children with Atopic Dermatitis: A Longitudinal Study.

机构信息

Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, Philadelphia, PA;

Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.

出版信息

J Immunol. 2021 May 1;206(9):2038-2044. doi: 10.4049/jimmunol.2001252. Epub 2021 Apr 16.

Abstract

Atopic dermatitis (AD) is a disease of immune dysregulation and skin barrier dysfunction with a relapsing, remitting course and has been associated with several different genetic risk variants. HLA represent a highly variable set of genes that code for cell surface protein molecules involved in the Ag-specific immune response, including the regulation or functioning of T cells, NK cells, and APCs. The purpose of this study was to evaluate associations between HLA class I polymorphisms and the progression of AD over time. We evaluated the associations of AD symptoms and HLA class I polymorphisms based on high-resolution two-field typing in a longitudinal cohort of children with AD (up to 10 y of follow-up). Seven hundred and ninety-two children were evaluated every 6 mo, resulting in 12,752 AD evaluations. Using generalized estimating equations and corrected values, B*44:02 was found to be associated with AD remission (1.83 [1.35, 2.47]; = 0.0015). The HLA-B residues at position 116 (d-aspartate) and 80 (T-threonine) were associated with remission (1.42 [1.13, 1.76], = 0.003; corrected = 0.028) and (1.45 [1.17, 1.80], = 0.0008; corrected = 0.0024), respectively. B80T is a killer-cell Ig-like receptor (KIR) site. Our findings reveal that two axes of immune response (T cell and NK cell) may influence disease progression. Identifying binding pocket changes in addition to other factors (e.g., allergens) that increase the risk or severity of AD can improve our understanding of the immunologic mechanisms associated with AD and may lead to personalized therapies for improving patient care.

摘要

特应性皮炎(AD)是一种免疫失调和皮肤屏障功能障碍的疾病,具有反复发作、缓解的特点,并与多种不同的遗传风险变异有关。HLA 代表一组高度可变的基因,这些基因编码参与抗原特异性免疫反应的细胞表面蛋白分子,包括 T 细胞、NK 细胞和 APC 的调节或功能。本研究旨在评估 HLA Ⅰ类基因多态性与 AD 随时间进展的相关性。我们根据 AD 儿童的纵向队列(最长 10 年的随访)进行的高分辨率两域分型,评估了 AD 症状与 HLA Ⅰ类基因多态性之间的相关性。792 名儿童每 6 个月接受一次评估,共进行了 12752 次 AD 评估。使用广义估计方程和校正的 值,发现 B*44:02 与 AD 缓解相关(1.83 [1.35, 2.47]; = 0.0015)。HLA-B 位置 116(天冬氨酸)和 80(苏氨酸)的残基与缓解相关(1.42 [1.13, 1.76], = 0.003;校正的 = 0.028)和(1.45 [1.17, 1.80], = 0.0008;校正的 = 0.0024),分别。B80T 是杀伤细胞免疫球蛋白样受体(KIR)位点。我们的研究结果表明,两个免疫反应轴(T 细胞和 NK 细胞)可能影响疾病进展。除了增加 AD 风险或严重程度的其他因素(例如过敏原)外,识别结合口袋的变化可以提高我们对与 AD 相关的免疫机制的理解,并可能为改善患者护理的个体化治疗提供依据。

相似文献

2
Association of KIR Genes and MHC Class I Ligands with Atopic Dermatitis.
J Immunol. 2021 Sep 15;207(6):1522-1529. doi: 10.4049/jimmunol.2100379. Epub 2021 Aug 18.
3
KIR Allelic Variation and the Remission of Atopic Dermatitis Over Time.
Immunohorizons. 2023 Jan 1;7(1):30-40. doi: 10.4049/immunohorizons.2200095.
4
NK cell killer Ig-like receptor repertoire acquisition and maturation are strongly modulated by HLA class I molecules.
J Immunol. 2014 Mar 15;192(6):2602-10. doi: 10.4049/jimmunol.1302843. Epub 2014 Feb 19.
5
Distribution of HLA-A, B alleles and polymorphisms of TAP and LMP genes in Korean patients with atopic dermatitis.
Clin Exp Allergy. 2001 Dec;31(12):1867-74. doi: 10.1046/j.1365-2222.2001.01042.x.
7
Human leukocyte antigen class-I variation is associated with atopic dermatitis: A case-control study.
Hum Immunol. 2021 Aug;82(8):593-599. doi: 10.1016/j.humimm.2021.04.001. Epub 2021 Apr 17.
8
Defining KIR and HLA Class I Genotypes at Highest Resolution via High-Throughput Sequencing.
Am J Hum Genet. 2016 Aug 4;99(2):375-91. doi: 10.1016/j.ajhg.2016.06.023.
9
Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells.
Cancer Immunol Immunother. 2009 Jun;58(6):855-65. doi: 10.1007/s00262-008-0601-7. Epub 2008 Oct 8.

引用本文的文献

3
Association of KIR2DL5, KIR2DS5, and KIR2DS1 allelic variation and atopic dermatitis.
Sci Rep. 2023 Jan 31;13(1):1730. doi: 10.1038/s41598-023-28847-y.
4
KIR Allelic Variation and the Remission of Atopic Dermatitis Over Time.
Immunohorizons. 2023 Jan 1;7(1):30-40. doi: 10.4049/immunohorizons.2200095.
5
To Be or Not to Be: The Case of Endoplasmic Reticulum Aminopeptidase 2.
Front Immunol. 2022 Jun 13;13:902567. doi: 10.3389/fimmu.2022.902567. eCollection 2022.
6
Immunogenomics of Killer Cell Immunoglobulin-Like Receptor (KIR) and HLA Class I: Coevolution and Consequences for Human Health.
J Allergy Clin Immunol Pract. 2022 Jul;10(7):1763-1775. doi: 10.1016/j.jaip.2022.04.036. Epub 2022 May 10.
7
Association of KIR Genes and MHC Class I Ligands with Atopic Dermatitis.
J Immunol. 2021 Sep 15;207(6):1522-1529. doi: 10.4049/jimmunol.2100379. Epub 2021 Aug 18.

本文引用的文献

1
2
Blood natural killer cell deficiency reveals an immunotherapy strategy for atopic dermatitis.
Sci Transl Med. 2020 Feb 26;12(532). doi: 10.1126/scitranslmed.aay1005.
3
The proteomic skin profile of moderate-to-severe atopic dermatitis patients shows an inflammatory signature.
J Am Acad Dermatol. 2020 Mar;82(3):690-699. doi: 10.1016/j.jaad.2019.10.039. Epub 2019 Oct 25.
4
Association between fine mapping thymic stromal lymphopoietin and atopic dermatitis onset and persistence.
Ann Allergy Asthma Immunol. 2019 Dec;123(6):595-601.e1. doi: 10.1016/j.anai.2019.08.018. Epub 2019 Sep 4.
5
Filaggrin sequencing and bioinformatics tools.
Arch Dermatol Res. 2020 Mar;312(2):155-158. doi: 10.1007/s00403-019-01956-3. Epub 2019 Aug 1.
7
Validation of five patient-reported outcomes for atopic dermatitis severity in adults.
Br J Dermatol. 2020 Jan;182(1):104-111. doi: 10.1111/bjd.18002. Epub 2019 Jul 24.
8
Atopic Dermatitis in US Adults: From Population to Health Care Utilization.
J Allergy Clin Immunol Pract. 2019 May-Jun;7(5):1524-1532.e2. doi: 10.1016/j.jaip.2019.01.005. Epub 2019 Jan 14.
9
Atopic dermatitis endotypes and implications for targeted therapeutics.
J Allergy Clin Immunol. 2019 Jan;143(1):1-11. doi: 10.1016/j.jaci.2018.10.032.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验